Effect on prostaglandin E₂ and leukotriene B₄ levels by local administration of glucocorticoid in human masseter muscle myalgia

Abstract

Our aim was to determine whether masseter muscle (M) and plasma (P) levels of prostaglandin E₂ (PGE₂) or leukotriene B₄ (LTB₄) are influenced by local glucocorticoid administration and whether such changes would be associated with corresponding changes in local pain or hyperalgesia. Eighteen patients with fibromyalgia and 15 with local masseter myalgia were examined immediately before and 2 weeks after intramuscular administration of glucocorticoid with regard to masseter muscle resting pain and tenderness to palpation, pressure pain threshold, maximum voluntary mouth opening (MVM), and pain on maximum voluntary mouth opening. The primary criteria for inclusion were presence of pain for a period of at least 3 months and tenderness to digital palpation in the masseter muscle region. At both visits microdialysis samples were obtained from the masseter muscle, and venous blood was collected for analysis of PGE₂ and LTB₄. Dialysate levels of M-PGE₂ did not change significantly after glucocorticoid administration, but reduction of masseter resting pain and increase of MVM were associated with decrease of M-PGE₂ in the patients with fibromyalgia. Dialysate levels of M-LTB₄ increased in both groups. In the patients with local myalgia the plasma level of LTB₄ also increased, and this increase was associated with a decrease of pain and masseter tenderness. In conclusion, this study shows that reduction of masseter level of PGE₂ after intramuscular glucocorticoid administration is associated with a decrease of resting pain in patients with fibromyalgia. In addition, the masseter muscle level of LTB₄ increases in patients with fibromyalgia and local myalgia.

• Glucocorticoid
• Leukotriene B4
• Microdialysis
• Myalgia
• Prostaglandin E2